CompletedNCT03197597
EUpertstrain 4 Study of Bordetella Pertussis Isolates
Studying Whooping cough
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Turku
- Principal Investigator
- Qiushui He, MD, PhDUniversity of Turku
- Intervention
- Strain isolation from the nasopharynx(other)
- Enrollment
- 265 enrolled
- Eligibility
- All sexes
- Timeline
- 2015 – 2016
Study locations (1)
- University of Turku, Turku, Finland
Collaborators
GlaxoSmithKline · Sanofi Pasteur, a Sanofi Company
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03197597 on ClinicalTrials.govOther trials for Whooping cough
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06827470Establishing a Controlled Human Infection Model of Pertactin-deficient Bordetella PertussisDalhousie University
- RECRUITINGPHASE4NCT0680352410-year Follow-up After a Single Dose Acellular Pertussis VaccinationMahidol University
- ACTIVE NOT RECRUITINGPHASE3NCT06798831Study Evaluating the Safety of a Recombinant Acellular Pertussis Vaccine in AdultsBioNet-Asia Co., Ltd.
- ACTIVE NOT RECRUITINGNCT06888076Study Evaluating the Safety of a Recombinant Acellular Pertussis Vaccine in Pregnant WomenBioNet-Asia Co., Ltd.
- RECRUITINGPHASE4NCT06903221A Phase 4, Randomised Vaccination Study in Healthy Adults to Investigate the Effects of Acellular Pertussis Vaccine on Colonisation with Bordetella Pertussis Using Controlled Human InfectionDimitri Diavatopoulos
- RECRUITINGNCT06286007Prevalence and Impact of Pertussis and RSV on Asthma Severity and ControlHospital Clinico Universitario de Santiago
- RECRUITINGNANCT05897879Impact of Bacterial Expression and Immune Response in the Severity of PertussisInstitut Pasteur
- RECRUITINGNANCT05847322Periscope Phase C Bordetella Pertussis Human Challenge Study With Delayed Antibiotic Therapy for 6 WeeksUniversity of Southampton